Zacks Investment Research
30 Sept 2026, 18:50 UTC · 1h ago
Verdict
Headline leans bearish. We score QURE −0.80 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.80strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
uniQure announced mixed additional data from phase I/II studies of ifezuntirgene inilparvovec for Huntington’s disease.
Newannounced on Sept. 29
So whatThe 37% share price drop suggests investors view the 'mixed' nature of the data as a significant risk to the drug's probability of FDA approval.
More negative than 99% of claims this week
Continue reading
5 related stories
More negative than 84% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Data shows ifezuntirgene inilparvovec appears to be slowing the progression of Huntington’s disease, with benefit maintained through month 48 on the total Functional Capacity (TFC) measure.
Newannounced on Sept. 29
So whatPositive long-term (4-year) durability data is critical for gene therapies, though it was insufficient to offset the overall 'mixed' result.
More positive than 80% of claims this week
Which stocks this story touches
More negative than 84% of ticker scores this week
The stock plunged 37% following the announcement of mixed data from phase I/II studies for Huntington's disease.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
6h ago
+0.0%
Price flat so far
$24.52 vs $24.51 close before publication (Sep 29) · not market-adjusted
QURE chart →
